USPTO serial 79325175
KELIX BIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 11, 2023
- Examiner
- EINSTEIN, MATTHEW T
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KELIX BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexander Lazouski
Alexander Lazouski LAZOUSKI IP LLCSUITE 1, 14726 BOWFIN TER.LAKEWOOD RANCH, FL 34202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals and natural remedies, namely, pharmaceutical preparations for the treatment of infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; medical preparations for the treatment of infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; injectable pharmaceuticals for the treatment of infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; injectable dermal fillers; biological preparations for medical purposes, namely, pharmaceutical preparations for the treatment of infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; pharmaceutical preparations for inhalers for the treatment of infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; vitamins; medicinal preparations for the treatment of infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; diagnostic preparations and materials, namely, diagnostic agents, preparations and substances for medical purposes; respiratory stimulants; compounds, namely, medicine for treating respiratory diseases; pharmaceutical products for treating respiratory diseases; dermatological pharmaceutical products | ACTIVE | — |
| 010 | Medical apparatus and instruments for treating infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; medical instruments for treating infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, nephrological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, blood disorders, lymphatic system and immune system related diseases and disorders; inhalers for therapeutic use; medical inhalers, namely, inhalers for medical use; physical therapy equipment in the nature of foam rollers, manually-operated resistance tubing, weighted balls | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kelix Bio Limited
- Other trademarks owned by Kelix Bio Limited
- Other trademarks owned by Kelix Bio Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named KELIX BIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 14, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 26, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 26, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 11, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 11, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 11, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 24, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 4, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 4, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 19, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 19, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 19, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 19, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 19, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 16, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 16, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 16, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 16, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 16, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 14, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 13, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 8, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 5, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 16, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 11, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |